WithdrawnPhase 2NCT05361109
Baricitinib for Cutaneous Dermatomyositis
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington
- Principal Investigator
- Kwanghoon Han, MDUniversity of Washington
- Intervention
- Baricitinib(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- University of Washington Medical Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05361109 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH